Non-Small Cell Lung Cancer

Knowing the DNA mutation or Epigenetic modification can save lives

Lung Cancer

Non-Small Cell
Lung Cancer

Adenocarcinoma

Mutation Status

Important for deciding therapy

For Example - Gefitinib works for EGFR L858R Mutation and EGFR Exon 19 Deletions

Check for mutational status before deciding the treatment regimen

Tvaster offers screening of EGFR L858R, T790M and Exon19 Del using blood sample

How do you know if you have EGFR-positive lung cancer?

In general, there are two ways to detect EGFR mutations. The best way is through comprehensive next-generation sequencing (NGS) and Liquid Biopsy. NGS is expensive and time taking procedure while Liquid Biopsy through ddPCR is highly sensitive, affordable and takes less than a week for results. Also, there may be some situations where a patient can’t undergo the biopsy needed to perform NGS, and so liquid biopsy is recommended. A liquid biopsy can look for specific biomarkers in a patient’s blood. Talk to your doctor to make sure one of these tests was performed.

Targeted Therapy Options (Example):

EGFR Exon 19 deletions and the L858R point mutation, is particularly responsive to Gefitinib and Erlotinib.

Osimertinib is a third-generation, orally available, irreversible, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor for numerous mutant forms of EGFR, including the secondarily-acquired resistance mutation T790M, L858R, and exon 19 deletions, thereby preventing EGFR-mediated signaling.

Knowing the DNA mutation or Epigenetic modification can save lives

Lung Cancer